Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8164091 | 1.00 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL30095400 | 1.00 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL31351763 | 0.90 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL4406348 | 0.90 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL16294347 | 0.90 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL28899214 | 0.85 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL28899211 | 0.85 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL9475477 | 0.82 | ERN1 (0.51) | ALDH1A1MAPTHTTTP53LMNA | |
| SCHEMBL30554494 | 0.81 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTHTTRAB9A | |
| SCHEMBL27444516 | 0.81 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294742-B | Fused ring ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-3227279-B1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | LILLY CO ELI (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3227279-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | Eli Lilly and Company (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9776992-B2 | 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |
| CN-104341396-A | Diaryl hydantoin derivative, as well as preparation method, medicine composition and application thereof | SHANGHAI PHARMACEUTICALS HOLDING CO LTD | 2015-02-11 | — | — | CN | disclosed |
| WO-2014167444-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233378-A1 | 1-OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | CDKN1A, API5, NUTF2 | ALDH1A1 505/4885L3MBTL1 1667/4885MAPT 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.